Skip to main content

Table 6 Summary of resource usage assumptions

From: Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist

Resource item

Mean

Sensitivity analyses

Rationale

Lower

Upper

Distribution

Acute treatment

Number of days of acute treatment (i.e. LMWH) required by a DVT patient

9.6

6

10

Dirichlet

EINSTEIN DVT [25]

SIGN guidelines [15]

Number of days of acute treatment (i.e. LMWH) required by a PE patient

9.7

7

13

Dirichlet

Mean duration from EINSTEIN PE [26]

Proportion of patients who self-inject LMWH (%)

92

64.40

100

Beta

The point estimate is taken from the assumptions in NICE CG92 [56]. The sensitivity range is an assumption

Proportion of remaining patients who require nurse assistance at home (%)

80

60

100%

Beta

These values are assumptions based on inputs determined for the NICE CG92 model

INR monitoring while on LMWH/VKA

Visits in first 3 months

9

5

15

Gamma

EINSTEIN DVT [25,51]

SIGN guidelines [15,51]

Visits each 3 months thereafter

5

2.5

10

Gamma

BNF [18,51]

Recurrent VTE: proportion treated as outpatients rather than inpatients

Recurrent DVT patients (%)

69

50

100

Beta

SIGN guidelines [15]

Incident PE patients (%)

17

0

30

Beta

Survey data

Other

Proportion of patients requiring NHS-funded transportation (%)

8.55

6

11

Beta

Survey data

Proportion of CTEPH patients who require PEA (%)

68.40

64.20

72.60

Beta

321 of 469 patients from Condliffe 2008 [43]

Length of admission post DVT, days

    

van Bellen 2014 [52]

LMWH/VKA

8*

4

10

  

Rivaroxaban

5*

3

9

  

Length of admission post PE, days

    

van Bellen 2014 [52]

LMWH/VKA

7*

5

10

  

Rivaroxaban

6*

4

9

  
  1. *Median values.
  2. BNF, British National Formulary; CTEPH, chronic thromboembolic pulmonary hypertension; DVT, deep vein thrombosis; INR, international normalized ratio; LMWH, low molecular weight heparin; NHS, National Health Service; NICE, National Institute for Health and Care Excellence; PE, pulmonary embolism; PEA, pulmonary endarterectomy; SIGN, Scottish Intercollegiate Guidelines Network; VKA, vitamin K antagonist; VTE, venous thromboembolism.